{"id":20848,"date":"2025-11-16T21:20:01","date_gmt":"2025-11-16T15:50:01","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=20848"},"modified":"2025-11-16T21:20:01","modified_gmt":"2025-11-16T15:50:01","slug":"syngene-%e0%a4%a6%e0%a4%b5%e0%a4%be-%e0%a4%85%e0%a4%a8%e0%a5%81%e0%a4%b8%e0%a4%82%e0%a4%a7%e0%a4%be%e0%a4%a8-%e0%a4%b5%e0%a4%bf%e0%a4%95%e0%a4%be%e0%a4%b8-%e0%a4%94%e0%a4%b0-%e0%a4%89","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/syngene-%e0%a4%a6%e0%a4%b5%e0%a4%be-%e0%a4%85%e0%a4%a8%e0%a5%81%e0%a4%b8%e0%a4%82%e0%a4%a7%e0%a4%be%e0%a4%a8-%e0%a4%b5%e0%a4%bf%e0%a4%95%e0%a4%be%e0%a4%b8-%e0%a4%94%e0%a4%b0-%e0%a4%89\/","title":{"rendered":"“Syngene \u2013 \u0926\u0935\u093e \u0905\u0928\u0941\u0938\u0902\u0927\u093e\u0928, \u0935\u093f\u0915\u093e\u0938 \u0914\u0930 \u0909\u0924\u094d\u092a\u093e\u0926\u0928 \u092e\u0947\u0902 \u0906\u092a\u0915\u0940 \u0926\u0941\u0928\u093f\u092f\u093e \u0915\u093e \u092d\u0930\u094b\u0938\u0947\u092e\u0902\u0926 \u0935\u0948\u091c\u094d\u091e\u093e\u0928\u093f\u0915 \u0938\u093e\u0925\u0940\u0964”"},"content":{"rendered":"

Syngene International Ltd \u2013 Detailed Stock Analysis Report (November 2025)<\/strong><\/p>\n

Technical Chart Analysis
\n<\/strong>Syngene\u2019s stock is currently showing a moderately bullish trend. The price is trading above its key moving averages, including the 20-day and 50-day exponential moving averages (EMA), signaling short- to medium-term strength. The Relative Strength Index (RSI) is around 60, indicating healthy buying momentum without being overbought. MACD (Moving Average Convergence Divergence) is positive, supporting bullish momentum. The stock has strong support near \u20b9650 and faces resistance around \u20b9685\u2013\u20b9700. Volume trends show consistent participation, confirming buyer interest. Given this technical setup, Syngene looks poised for a gradual uptrend, with cautious monitoring near resistance zones.<\/p>\n

Fundamental Analysis
\n<\/strong>Syngene International is a leading contract research and manufacturing organization (CRAMS) in India, serving global pharmaceutical and biotechnology companies. The company\u2019s revenue in the last quarter (Q2 FY26) was \u20b9911 crore, growing modestly by 2% YoY, while EBITDA declined 18% primarily due to inventory correction in the CDMO (Contract Development and Manufacturing Organization) segment. Reported PAT dropped 37%, reflecting short-term pressure on profitability. However, long-term prospects remain positive due to robust pipelines in biologics, strategic expansions, and investments in peptide capabilities. Syngene\u2019s strong client relationships, expanding service segments, and operational efficiencies bode well for future growth. The stock currently trades at a high P\/E multiple (~57x), implying expectations of future earnings growth.<\/p>\n

Recent News & Upcoming Event
\n<\/strong>Syngene\u2019s management will hold an analyst call to discuss Q2 FY26 results.
\nParticipation in upcoming international pharma conferences (e.g., CPHI India in November 2025).
\nAnnounced strategic focus on biologics, peptide APIs, and novel drug delivery systems.
\nMarket analysts suggest cautious optimism due to recent margin contraction but emphasize long-term growth potential.<\/p>\n

Positive Points
\n<\/strong>Leadership position in Indian CRAMS with global clientele.
\nDiversification into biologics and specialty peptides increasing growth visibility.
\nStrong cash flows, low debt, and healthy balance sheet.
\nOngoing innovation and investment into newer service platforms.<\/p>\n

Negative Points
\n<\/strong>Recent margin contraction impacting short-term profitability.
\nModerate revenue growth amid inventory corrections.
\nHigh valuation may limit near-term upside without earnings acceleration.
\nDependency on global pharma industry cyclicality and contract renewals.<\/p>\n

Disclaimer & Disclosure
\n<\/strong>This analysis is for informational purposes only and does not constitute a buy or sell recommendation. Stock investments carry risk and market volatility. Investors should perform due diligence and consult a registered financial advisor prior to making investment decisions. No personal or organizational stake is held in Syngene International by the author.<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[400,130,163,112,183,121,235,129,162,168],"class_list":["post-20848","article","type-article","status-publish","hentry","article-category-learn","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-financialplanning","article-tags-investingtips","article-tags-investment-opportunities","article-tags-nifty50","article-tags-stock-market-tips","article-tags-stockmarket","article-tags-stockmarkettips"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/20848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=20848"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=20848"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=20848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}